GlobeNewswire Inc | Sep 16, 2021 08:00AM EDT

September 16, 2021

BALA CYNWYD, Pa., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,today announced that company management will participate in 1x1 investor meetings at the SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1x1 Event. The event is taking place virtually September 22-23, 2021.

AboutLarimar Therapeutics

Larimar Therapeutics, Inc.(Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimars lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in theU.S.as a potential treatment for Friedreich's ataxia.Larimaralso plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Investor Contact:Joyce AllaireLifeSci Advisorsjallaire@lifesciadvisors.com(212) 915-2569

Company Contact:Michael CelanoChief Financial Officermcelano@larimartx.com(484) 414-2715